Solving Antimicrobial Resistance

The world is facing a rapidly escalating health crisis known as antimicrobial resistance (AMR). This means that the antibiotics we use to fight infections are becoming less effective as the bacteria they seek to kill become more resistant.

While scientists have been aware of the crisis for many years, innovative solutions have been scarce. In fact, it has been over 30 years since a new class of antibiotics has been introduced to the market

Without a transformational innovation in the treatment of infections, it has been estimated that by 2050, antibiotic-resistant bacterial infections could kill 10 million people a year (which is more than all cancer deaths combined). This would have a global economic impact of $100 trillion. 

Viotika Life Sciences has assembled a team of leading investigators and technicians to advance research into a new approach to fighting certain types of bacteria that are becoming resistant to conventional antibiotics. We believe we have the necessary transformational innovation in hand. 

The Viotika solution is a new platform from which to target a protein or disrupt a process contained exclusively within pathogenic bacteria while not affecting normal, healthy bacteria. Variants have been developed as well, with the perspective to target selected pathogenic species. Specifically, and in brief, the work is focused on Na+- translocating NADH: ubiquinone oxidoreductase (Na+-NQR), a key respiratory enzyme in many microbial pathogens. 

The research into this approach took root 2001. A series of drugs has already been developed and tested successfully in preclinical work. 

Viotika Life Sciences Inc. was formed in 2018 to expand and accelerate the research and conduct clinical trials. Our intellectual property is protected through a series of patents.

The company does not intend to manufacture the drug for sale on its own. Our strengths are in research and development. As the work moves forward, Viotika Life Sciences Inc. will seek appropriate partners who are equipped to mass-produce this novel antibiotic and bring it to market.

The future well-being of humanity depends on solving the AMR puzzle. We believe we have the solution.

Our Vision

A world where no one dies because of antimicrobial resistance.

Our Mission

To advance our breakthrough, generational science; to develop new tools to fight bacterial infections; and to prepare these tools for market, with the support of visionary investors and partners.

Publications

The following papers shine a light on the foundations of Viotika’s science and its novel platform for addressing the global challenge of antimicrobial resistance (AMR).

Na+-NQR (Na+-translocating NADH:ubiquinone oxidoreductase) as a novel target for antibiotics
Pavel Dibrov, Elena Dibrov
FEMS Microbiology Reviews (2017), 41(5), 653–671
https://doi.org/10.1093/femsre/fux032

Development of a novel rationally designed antibiotic to inhibit a nontraditional bacterial target
Pavel Dibrov, Elena Dibrov, Thane G. Maddaford, Melissa Kenneth, Jordan Nelson, Craig Resch
Canadian Journal of Physiology and Pharmacology (2017), 95, 595–603
https://doi.org/10.1139/cjpp-2016-0505

Effects of chromosomal deletion of the operon encoding the multiple resistance and pH-related antiporter in Vibrio cholerae
Alisha M. Aagesen, Carla B. Schubiger, Eric C. Hobson, Pavel Dibrov, Claudia C. Häse
Microbiology (2016), 162, 1–12
https://doi.org/10.1099/mic.0.000384

The past and present of sodium energetics: May the sodium-motive force be with you
Armen Y. Mulkidjanian, Pavel Dibrov, Michael Y. Galperin
Biochimica et Biophysica Acta (BBA) – Bioenergetics (2008), 1777(7–8), 985–992
https://doi.org/10.1016/j.bbabio.2008.04.028

Chlamydia pneumoniae Stimulates Proliferation of Vascular Smooth Muscle Cells Through Induction of Endogenous Heat Shock Protein 60
Satoru Hirono, Elena Dibrov, Cecilia Hurtado, Annette Kostenuk, Robin Ducas
Circulation Research (2003), 93, 710–716
https://doi.org/10.1161/01.RES.0000095720.46043.F2

The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae
He Hu, Guangming Zhong
Journal of Clinical Investigation (1999), 103(5), 747–753
https://doi.org/10.1172/JCI4582

The Viotika Team

Business Development and Administration

  • Charles (Chuck) LaFlèche FCPA, FCMA
    President, CEO, & CFO
  • Susan Hirst
    Executive Assistant
  • Christiane LaFlèche
    Accountant
  • Rob McCarthy
    Project Manager
  • Dr. Linda Pullan, Pullan Consulting
    Business Development
  • Norm Dupas, nivå10 Corp
    Business Development
  • Stu Slayen, Stu Slayen Consulting
    Communications

Research

  • Dr. Pavel Dibrov
    Chief Scientific Advisor
  • Dr. Elena Dibrov
    Laboratory Director
  • Dr. Alex Dibrov
    In Silico (Computer) Modelling
  • Dr. Peter Bernstein, PhaRmaB LLC
    Medicinal Chemistry Consultant
  • Thane Maddaford
    Senior Technician
  • Dr. Munhati Mourin
    Research Associate
  • Dr. Kim O’Hara
    Research Associate
  • Dr. Craig Resch
    Research Associate

Board of Directors

  • Charles (Chuck) LaFlèche FCPA, FCMA
  • Ken Blair

Advisors

  • Dr. Peter Bernstein
    Medicinal Chemistry Consultant
  • Dr. Igor Osipov
    International Strategy

Viotika Life Sciences Inc.
Suite 323, J-390 Provencher Blvd.
Winnipeg, MB R2H 0H1

info@viotika.com
(204) 235-3003